Showing 22,152 news articles about PEP

Filters Content type: Editors' picks Topic: PEP

Post-exposure prophylaxis involves taking a 28-day course of anti-HIV drugs, after possible exposure to HIV. It may be used by healthcare workers (occupational PEP) or after sex (post-exposure prophylaxis after sexual exposure, PEPSE, also known as non-occupational PEP or nPEP).

Activism & civil society

A Personal Farewell to Aidsmap from the Activist Who Was There

Editor's pick
My Fabulous Disease
17 July 2024
Conference announcements & declarations

Visa problems ahead of International AIDS Conference in Munich

Editor's pick
Deutsche Aidshilfe
17 July 2024
Access to healthcare

2024 HIV Mid-Year Market Memo

Editor's pick
Clinton Health Access Initiative
17 July 2024
HIV treatment

New Unitaid report: World's leading HIV drug proven to have reduced global CO2 emissions by 26 million tons

Editor's pick
Unitaid
15 July 2024
Chemsex & recreational drug use

Does Cannabis Reduce Inflammation in People With HIV?

Editor's pick
POZ
12 July 2024
Government, leadership & policy

How Budget Cuts to Global AIDS Program PEPFAR Would Impact HIV Care

Editor's pick
POZ
12 July 2024
Pregnancy and vertical transmission

Navigating Pregnancy While Living With HIV: A Mother’s Journey and Advice

Editor's pick
TheBody
12 July 2024
Access to healthcare

New HIV drug can only offer hope of ending AIDS if all have access, UNAIDS says

Editor's pick
UNAIDS
12 July 2024
Cancer

US: HIV Clinical Guidelines Now Recommend High Resolution Anoscopy as Part of Anal Cancer Screening Program for People with HIV

Editor's pick
National Institutes of Health
10 July 2024
Injectable & long-acting HIV treatment

Long-Acting Injectables Are Effective for Homeless People

Editor's pick
POZ
10 July 2024
Conference announcements & declarations

What You Need To Know About Protesting at AIDS 2024 in Munich

Editor's pick
TheBody
10 July 2024
Government, leadership & policy

UK: The government that could end new HIV cases

Editor's pick
Terrence Higgins Trust
9 July 2024
Pharmaceutical industry

After Gilead and J&J lawsuits, distributor Safe Chain sees its owners charged in criminal indictment

Editor's pick
FiercePharma
5 July 2024
Activism & civil society

Communicating HIV science: the past, present and future

Editor's pick
HIV Cure
5 July 2024
HIV & criminal law

CHLP Denounces New Law in Tennessee that Further Criminalizes People Living with HIV

Editor's pick
The Center for HIV Law and Policy
5 July 2024
Kidney problems

Patients with HIV who get therapy may have similar CKD results vs. patients who defer care

Editor's pick
Healio
5 July 2024
Finance & funding

What a PEPFAR funding cut could mean for the HIV response in Botswana

Editor's pick
Devex (requires free registration)
5 July 2024
Global health initiatives

Biden administration plans major cuts to AIDS relief programs in Africa

Editor's pick
POLITICO
5 July 2024
Health services & systems

Does AI Have a Place in the HIV Community?

Editor's pick
TheBody
27 June 2024
PrEP policies & guidelines

US: Government-Mandated PrEP Coverage Mostly Survives Appeals Court Ruling; Threats Still Loom

Editor's pick
TheBody
27 June 2024
Epidemiology

Mississippi HIV/AIDS Advocates Say Their State Is Falling Perilously Short on Ending the HIV Epidemic Markers

Editor's pick
TheBody
27 June 2024
Access to healthcare

‘Inward, Technocratic’ MSF Leadership Under Global Pressure to Reverse Decision to Close Access Campaign

Editor's pick
Health Policy Watch
26 June 2024
Adherence

Overcoming the Challenges of Adhering to Injectable ART and PrEP

Editor's pick
Infectious Disease Special Edition
26 June 2024
PrEP programmes & uptake

How PrEP4Teens Constructed a Rigorously Researched, Teen-Led Sexual-Health Program

Editor's pick
TheBodyPro
26 June 2024